ArticleApplied microbiology and biotechnology2025
Hermetia illucens chitosan: indirect and direct antimicrobial activity of an innovative biopolymer for clinical and pharmaceutical applications.
Article in Applied microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The increasing spread of antimicrobial resistance has prompted the search for innovative alternatives to conventional antibiotics. Chitosan, a biopolymer derived from chitin, is known for its broad-spectrum antimicrobial activity. This study evaluated both direct and indirect antimicrobial activity of chitosan obtained from Hermetia illucens, a novel and sustainable source compared to the traditionally crustacean-derived biopolymer. Chitosan produced from H. illucens larvae, pupal exuviae and adults, through heterogeneous and homogeneous deacetylation, was tested for both its indirect and direct antimicrobial effects. The indirect effect was evaluated by measuring the induction of Human Beta-Defensin-2 (HBD-2) expression in HaCaT keratinocytes stimulated with lipopolysaccharide of Salmonella typhimurium, a Gram-negative bacterium. The direct antimicrobial activity was assessed against Gram-positive pathogens (Enterococcus faecalis, Staphylococcus epidermidis, and Streptococcus agalactiae), using a microdilution assay and plate colony count. Results demonstrated significant bacteriostatic effects at 0.5 mg/mL, with some samples, particularly the homogeneous unbleached pupal exuviae chitosan and the heterogeneous unbleached larvae chitosan, comparable to or even superior to commercial chitosan in terms of biological activity. Furthermore, insect-chitosan significantly up-regulated HBD-2 expression, suggesting immunomodulatory activity. These findings validated H. illucens as a promising alternative source of chitosan with dual antimicrobial activity, and supported its potential use in clinical, pharmaceutical and biomedical applications. KEY POINTS: • Insect-chitosan activates innate immunity via strong HBD-2 induction • Chitosan samples showed notable growth-inhibition toward key Gram-positive strains • Hermetia illucens chitosans provide efficacy comparable or superior to the commercial biopolymer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.